IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme
This includes £0.7m from the Volplex and Isoplex Distribution and Sale agreement. Product sales were up 19% to £13.4m (2009: £11.2m) and pre-tax profit up 30% to £2.6m (2009: £2.0m) post exceptional items of £0.4m (2009: £0.6m). Basic earnings per share were 7.3p (2009: 9.1p).
Consensus estimates were for pre-tax profit of £2.98m and eps of 8.23p, however, there was a big spread between the 2 analysts covering this one (6.7p…
Previous article Next article